Business
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2404,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OymR4EMJXxDB_ihte0qgRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf","width":960,"height":89},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bSfKUplulzMjJbmMLxJsrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yMjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a02e119d55f341dd41019c8f770f02bf","width":1200,"height":112}},"lazy":false},{"type":"text","content":"Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson’s nearly two decades of innovation in the disease area","length":177,"tagName":"p"},{"type":"text","content":"Lead asset shows potential to overcome common types of resistance to treatment in prostate cancer with a precision tumor cell-killing approach","length":142,"tagName":"p"},{"type":"text","content":"Includes novel technology platform capable of developing the next generation of highly targeted oral treatments for multiple solid tumors, including breast and lung cancers","length":172,"tagName":"p"},{"type":"text","content":"NEW BRUNSWICK, N.J., November 17, 2025--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions.","length":589,"tagName":"p"},{"type":"text","content":"The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer, of which new diagnoses are projected to reach 1.7 million globally by 20301. Given the existing unmet need, this once-daily therapy has the potential to transform patient outcomes with its novel precision cancer cell-killing approach that can o...